{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:06:52Z","timestamp":1785445612352,"version":"3.56.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Biologic therapies have revolutionized psoriasis management, yet treatment responses remain highly heterogeneous. A distinct subgroup of patients, termed super responders (SRs), achieves exceptionally rapid, complete, and sustained responses to biologic therapies. Understanding this phenotype is critical for advancing precision medicine in psoriasis. This review summarizes the latest advances in SRs, focusing on definitions, predictors, and therapeutic implications. Definitions of SRs vary widely across studies, differing in both temporal criteria and efficacy endpoints. Meanwhile, emerging evidence suggests a convergent trend toward multidimensional definitions that combine rapid and complete skin clearance (typically PASI 100 within 3\u20136 months) and sustained low disease activity during long-term follow-up (often \u22651 year). Convergent predictors of SRs include a lower body mass index (BMI), a favorable metabolic profile, biologic-na\u00efve status and emerging genetic and immunological markers. As a potentially biologically distinct subgroup, SRs present a unique opportunity for treatment optimization, including dosing-interval extension and treatment-free remission in selected patients, offering the potential to sustain efficacy while reducing drug exposure, cost, and patient burden. Key research priorities include establishing consensus definitions, developing validated predictive models, and generating long-term safety data to guide treatment optimization. Integrating the SRs concept into practice may transform psoriasis care from fixed, lifelong regimens to adaptive, evidence-based management grounded in precision medicine.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1744951","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:47:16Z","timestamp":1773384436000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Super responders to biologic therapy in psoriasis: definitions, predictors, and implications for precision medicine"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiya","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venerology, Rare Diseases Center, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Weifang People\u2019s Hospital","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Weifang People\u2019s Hospital","place":["Weifang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549\u20136","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: what is the evidence","volume":"182","author":"Korman","year":"2020","journal-title":"Br J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713313","article-title":"Challenges and future trends in the treatment of psoriasis","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1186455","article-title":"Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies","volume":"14","author":"Brembilla","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad280","article-title":"How to define a \u2018super-responder\u2019 to biologics in psoriasis studies","volume":"189","author":"Thomas","year":"2023","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e049822","DOI":"10.1136\/bmjopen-2021-049822","article-title":"IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)","volume":"11","author":"Eyerich","year":"2021","journal-title":"BMJ Open"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Sch\u00e4kel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2463","article-title":"Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial","volume":"160","author":"Eyerich","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18474","article-title":"Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator\u2019s Global Assessment scores predict complete skin clearance","volume":"36","author":"Reich","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01394-2","article-title":"Predictive factors for super responder status and long-term effectiveness of guselkumab in psoriasis: a multicenter retrospective study","volume":"15","author":"Mortato","year":"2025","journal-title":"DermatolTher (Heidelb)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13175175","article-title":"Characterization of super-responder profile in chronic plaque psoriatic patients under guselkumab treatment: a long-term real-life experience","volume":"13","author":"Marcelli","year":"2024","journal-title":"J Clin Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13143992","article-title":"Blood-count-derived inflammatory markers as predictors of response to biologics and small-molecule inhibitors in psoriasis: a multicenter study","volume":"13","author":"Morariu","year":"2024","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1898528","article-title":"Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis","volume":"33","author":"Feldman","year":"2022","journal-title":"J Dermatol Treat"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01280-9","article-title":"Real-world performance of a new strategy for off-label use of guselkumab in moderate to severe psoriasis: super-responder patients as the epitome of efficacy and optimisation","volume":"43","author":"Herranz-Pinto","year":"2023","journal-title":"Clin Drug Investig"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15784","article-title":"Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series","volume":"61","author":"Ruiz-Villaverde","year":"2022","journal-title":"Int J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/life12091412","article-title":"Super-responders in moderate-severe psoriasis under guselkumab treatment: myths, realities and future perspectives","volume":"12","author":"Ruiz-Villaverde","year":"2022","journal-title":"Life (Basel)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18825","article-title":"Brodalumab in plaque psoriasis: Real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks","volume":"37","author":"Rompoti","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18126","article-title":"Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study","volume":"36","author":"Loft","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2025.02.063","article-title":"Characterization and treatment outcomes of biologic therapy in super-responders and biologic-refractory psoriasis patients: A single-center retrospective study in China","volume":"93","author":"Liu","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2023.4555","article-title":"Predictors of psoriasis area and severity index 100 response in korean patients with moderate-to-severe plaque psoriasis receiving biologics","volume":"33","author":"Kim","year":"2023","journal-title":"Eur J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad446","article-title":"Characteristics of \u2018super responders\u2019 and \u2018super nonresponders\u2019 to first biologic monotherapy for psoriasis: a nested case-control study","volume":"190","author":"Mason","year":"2024","journal-title":"Br J Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19682","article-title":"Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years","volume":"38","author":"Mastorino","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19310","article-title":"Super-responders in psoriasis under interleukin 23 inhibitor treatments, experience in two centres","volume":"37","author":"Men\u00e9ndez S\u00e1nchez","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"259270","DOI":"10.1080\/14712598.2021.1862082","article-title":"HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis","volume":"21","author":"Morelli","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2331782","article-title":"Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-year","volume":"35","author":"Liu","year":"2024","journal-title":"J Dermatol Treat"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19464","article-title":"A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS)","volume":"38","author":"Gargiulo","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.017","article-title":"From the medical board of the national psoriasis foundation: treatment targets for plaque psoriasis","volume":"76","author":"Armstrong","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15659","article-title":"High-resolution HLA typing identifies a new \u2018super responder\u2019 subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02\/HLA-C*04, in response to ustekinumab","volume":"33","author":"Talamonti","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14731","article-title":"Superresponders\u201d at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors","volume":"32","author":"Mastorino","year":"2023","journal-title":"Exp Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2018.03.007","article-title":"Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis","volume":"86","author":"Shan","year":"2019","journal-title":"Joint Bone Spine"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.1677","article-title":"Clinical characteristics associated with response to biologics in the treatment of psoriasis: a meta-analysis","volume":"160","author":"Hjort","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","article-title":"Drug survival of interleukin (IL)\u201317 and IL\u201323 inhibitors for the treatment of psoriasis: a retrospective multi\u2013country, multicentric cohort study","volume":"23","author":"Torres","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.5114\/reum\/162995","article-title":"Effect of low-calorie diet on psoriasis severity index, triglycerides, liver enzymes, and quality of life in psoriatic patients with non-alcoholic fatty liver disease","volume":"61","author":"Ismail","year":"2023","journal-title":"Reumatologia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0186575","DOI":"10.1371\/journal.pone.0186575","article-title":"Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab","volume":"12","author":"Scaldaferri","year":"2017","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2014.900541","article-title":"The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial","volume":"14","author":"Al-Mutairi","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jaad.2017.04.1133","article-title":"Systematic review and meta-analysis of the association between psoriasis and metabolic syndrom","volume":"77","author":"Rodr\u00edguez-Z\u00fa\u00f1iga","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2174\/1871530319666191008170409","article-title":"The association of metabolic syndrome and psoriasis: a systematic review and meta-analysis of observational study","volume":"20","author":"Choudhary","year":"2020","journal-title":"Endocr Metab Immune Disord Drug Targ"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S514249","article-title":"Real-world experience of bimekizumab in a cohort of 109 patients over 48 weeks and identification of predictive factors for an early super response and risk of adverse events","volume":"15","author":"Fratton","year":"2025","journal-title":"Psoriasis (Auckl)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01755-0","article-title":"Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies","volume":"45","author":"Bellinato","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16705","article-title":"Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study","volume":"179","author":"Costanzo","year":"2018","journal-title":"Br J Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10111977","article-title":"Allelic variants of hla-c upstream region, psors1c3, mica, tnfa and genes involved in epidermal homeostasis and barrier function influence the clinical response to anti-IL-12\/IL-23 treatment of patients with psoriasis","volume":"10","author":"Morelli","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s00403-025-04132-y","article-title":"The influence of genetic factors on the clinical manifestations and response to systemic treatment of plaque psoriasi","volume":"317","author":"Majewski","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf010","article-title":"Drug survival, effectiveness, and safety of guselkumab for moderate-to-severe psoriasis for up to 4 years","volume":"50","author":"Mastorino","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136432","article-title":"Serum IL-18\/IL-13 ratio predicts super response to secukinumab in patients with psoriasis","volume":"26","author":"Ziolkowska-Banasik","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","first-page":"269rv1","DOI":"10.1126\/scitranslmed.3010641","article-title":"Resident memory T cells in human health and disease","volume":"7","author":"Clark","year":"2015","journal-title":"Sci Transl Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.374","article-title":"Gone but not forgotten: lesional memory in psoriatic skin","volume":"131","author":"Clark","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.03.014","article-title":"Pathogenic role of tissue-resident memory T cells in autoimmune diseases","volume":"17","author":"Wu","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1625","article-title":"Defining on-treatment remission in plaque psoriasis: a consensus statement from the national psoriasis foundation","volume":"161","author":"Armstrong","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-017-3780-8","article-title":"Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review","volume":"37","author":"Lau","year":"2017","journal-title":"Rheumatol Int"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00519-9","article-title":"Sustained remission and outcomes with abatacept plus methotrexate following stepwise dose de-escalation in patients with early rheumatoid arthritis","volume":"10","author":"Emery","year":"2023","journal-title":"Rheumatol Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01448-z","article-title":"Dose tapering of biologics in patients with psoriasis: a scoping review","volume":"81","author":"Michielsens","year":"2021","journal-title":"Drugs"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00949-5","article-title":"Disease modification in psoriasis: future prospects for long-term remission","volume":"26","author":"Ranzinger","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01229-6","article-title":"Comparison of drug-free remission after the end of phase III trials of three different anti-il-23 inhibitors in psoriasis","volume":"14","author":"Hsieh","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"AB222","DOI":"10.1016\/j.jaad.2024.07.883","article-title":"50236 GUIDE trial results after withdrawal in part 3: long-term remission in patients with psoriasis treated with guselkumab within 15 months from onset of symptoms","volume":"91","author":"Sch\u00e4kel","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.01.029","article-title":"Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: a nationwide cohort study","volume":"88","author":"Nielsen","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16915","article-title":"Euroguiderm guideline on the systemic treatment of psoriasis vulgaris - Part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"10688","DOI":"10.1038\/s41467-024-54559-6","article-title":"Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases","volume":"15","author":"Seremet","year":"2024","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14508","article-title":"German S3-guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: Treatment goals and treatment recommendations","volume":"19","author":"Nast","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S328460","article-title":"Towards personalized medicine in psoriasis: current progress","volume":"12","author":"Camela","year":"2022","journal-title":"Psoriasis (Auckl)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713313","article-title":"Challenges and future trends in the treatment of psoriasis","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1002629","article-title":"Immuniverse consortium: multi-omics integrative approach in personalized medicine for immune-mediated inflammatory diseases","volume":"13","author":"Vetrano","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1744951\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:47:18Z","timestamp":1773384438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1744951\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":67,"alternative-id":["10.3389\/fimmu.2026.1744951"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1744951","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"article-number":"1744951"}}